Nanog priming before full reprogramming may generate germ cell tumours

European Cells and Materials

Volumn 22, Issue , 2011, Pages 258-274

  Grad, I ^a,b   Hibaoui, Y ^a   Jaconi, M ^c   Chicha, L ^d   Bergstrom Tengzelius R ^e   Sailani, M R ^c   Pelte, M F ^c   Dahoun, S ^c   Mitsiadis, T A ^f   Tohonen V ^e   Bouillaguet, S ^b   Antonarakis, S E ^c   Kere, J ^e   Zucchelli, M ^e   Hovatta, O ^e   Feki, A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cancer; Cancer stem cells; Germ cell tumour; Induced pluripotent stem cells; NANOG; Pluripotency; Reprogramming; Stem cells

Indexed keywords

BINDING PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN LIN28; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; LIN 28 PROTEIN, HUMAN; LIN-28 PROTEIN, HUMAN; NANOG PROTEIN, HUMAN; POU5F1 PROTEIN, HUMAN; RNA BINDING PROTEIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ARTICLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; GENE OVEREXPRESSION; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; KARYOTYPE; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; SEQUENCE ANALYSIS;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KARYOTYPE; MICE; MICE, SCID; NEOPLASMS, GERM CELL AND EMBRYONAL; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, RNA; SOXB1 TRANSCRIPTION FACTORS;

EID: 84857130181     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v022a20     Document Type: Article

References (43)

1. Bettiol E, Clement S, Krause KH, Jaconi ME (2006) Embryonic and adult stem cell-derived cardiomyocytes: lessons from in vitro models. Rev Physiol Biochem Pharmacol 157: 1-30.
2. Blum B, Benvenisty N (2009) The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 8: 3822-3830.
3. Bomken S, Fiser K, Heidenreich O, Vormoor J (2010) Understanding the cancer stem cell. Br J Cancer 103: 439-445.
4. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
5. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A (2003) Functional expression cloning of nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643-655.
6. Chicha L, Feki A, Boni A, Irion O, Hovatta O, Jaconi M (2011) Human pluripotent stem cells differentiated in fully defined medium generate hematopoietic CD34 and CD34 progenitors with distinct characteristics. PLoS One 6: e14733.
7. Ezeh UI, Turek PJ, Reijo RA, Clark AT (2005) Human embryonic stem cell genes Oct4, Nanog, Stellar, and Gdf3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265.
8. Freberg CT, Dahl JA, Timoskainen S, Collas P (2007) Epigenetic reprogramming of Oct4 and Nanog regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell 18: 1543-1553.
9. Gopalan A, Dhall D, Olgac S, Fine SW, Korkola JE, Houldsworth J, Chaganti RS, Bosl GJ, Reuter VE, Tickoo SK (2009) Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, Oct3/4, Sox2 and Gdf3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol 22: 1066-1074.
10. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N, Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisua Belmonte JC, Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, Zhang K (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471: 63-67.
11. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163-4169.
12. Hochedlinger K, Yamada Y, Beard C, Jaenisch R (2005) Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121: 465-477.
13. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460: 1132-1135.
14. Hovatta O, Jaconi M, Tohonen V, Bena F, Gimelli S, Bosman A, Holm F, Wyder S, Zdobnov EM, Irion O, Andrews PW, Antonarakis SE, Zucchelli M, Kere J, Feki A (2010) A teratocarcinoma-like human embryonic stem cell (hESC) line and four hESC lines reveal potentially oncogenic genomic changes. PLoS One 5: e10263.
15. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, Ng S, Sourour M, Hamalainen R, Olsson C, Lundin K, Mikkola M, Trokovic R, Peitz M, Brustle O, Bazett-Jones DP, Alitalo K, Lahesmaa R, Nagy A, Otonkoski T (2011) Copy number variation and selection during reprogramming to pluripotency. Nature 471: 58-62.
16. Inunza J, Gertow K, Strömberg MA, Matilainen E, Blennow E, Skottman H, Wolbank S, Ahrlund-Richter L, Hovatta O (2005) Derivation of human embryonic stem cell lines in serum replacement medium using postnatal human fibroblasts as feeder cells. Stem Cells 23: 544-549.
17. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG (2009) Functional evidence that the self-renewal gene Nanog regulates human tumor development. Stem Cells 27: 993-1005.
18. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Belmonte JC (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460: 1140-1144.
19. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee S, Barrero MJ, Ku S, Martynova M, Semechkin R, Galat V, Gottesfeld J, Izpisua Belmonte JC, Murry C, Keirstead HS, Park HS, Schmidt U, Laslett AL, Muller FJ, Nievergelt CM, Shamir R, Loring JF (2011) Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and IPSCs during reprogramming and time in culture. Cell Stem Cell 8: 106-118.
20. Lindgren AG, Natsuhara K, Tian E, Vincent JJ, Li X, Jiao J, Wu H, Banerjee U, Clark AT (2011) Loss of PTEN causes tumor initiation following differentiation of murine pluripotent stem cells due to failed repression of Nanog. PLoS One 6: e16478.
21. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K (2008) A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3: 340-345.
22. Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, Plath K, Lowry WE, Benvenisty N (2010) Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7: 521-531.
23. Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R (2010) P53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 31: 1501-1508.
24. Moriguchi H, Chung RT, Sato C (2010) Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. Hepatology 51: 1088-1089.
25. Nettersheim D, Biermann K, Gillis AJ, Steger K, Looijenga LH, Schorle H (2011) Nanog promoter methylation and expression correlation during normal and malignant human germ cell development. Epigenetics 6: 114-122.
26. Neveu P, Kye MJ, Qi S, Buchholz DE, Clegg DO, Sahin M, Park IH, Kim KS, Daley GQ, Kornblum HI, Shraiman BI, Kosik KS (2010) Microrna profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 7: 671-681.
27. Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448: 313-317.
28. Pasi CE, Dereli-Oz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G, Trono D, Pelicci PG, Halazonetis TD (2011) Genomic instability in induced stem cells. Cell Death Differ 18: 745-753.
29. Peirson SN, Butler JN, Foster RG (2003) Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31: e73.
30. Silva J, Chambers I, Pollard S, Smith A (2006) Nanog promotes transfer of pluripotency after cell fusion. Nature 441: 997-1001.
31. Soini Y, Paakko P, Lehto VP (1998) Histopathological evaluation of apoptosis in cancer. Am J Pathol 153: 1041-1053.
32. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G (2009) Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27: 543-549.
33. Stadtfeld M, Hochedlinger K (2010) Induced pluripotency: history, mechanisms, and applications. Genes Dev 24: 2239-2263.
34. Ström S, Holm F, Bergström R, Strömberg AM, Hovatta O (2010) Derivation of 30 human embryonic stem cell lines - improving the quality. In Vitro Cell Dev Biol Anim 46: 337-344.
35. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
36. Tapia N, Scholer HR (2010) P53 connects tumorigenesis and reprogramming to pluripotency. J Exp Med 207: 2045-2048.
37. Tiemann U, Sgodda M, Warlich E, Ballmaier M, Scholer HR, Schambach A, Cantz T (2011) Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. Cytometry A 79: 426-435.
38. Tysnes BB (2010) Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia 12: 506-515.
39. Unger C, Gao S, Cohen M, Jaconi M, Bergstrom R, Holm F, Galan A, Sanchez E, Irion O, Dubuisson JB, Giry-Laterriere M, Salmon P, Simon C, Hovatta O, Feki A (2009) Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells. Hum Reprod 24: 2567-2581.
40. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K (2009) Immortalization eliminates a roadblock during cellular reprogramming into IPS cells. Nature 460: 1145-1148.
41. Werbowetski-Ogilvie TE, Bosse M, Stewart M, Schnerch A, Ramos-Mejia V, Rouleau A, Wynder T, Smith MJ, Dingwall S, Carter T, Williams C, Harris C, Dolling J, Wynder C, Boreham D, Bhatia M (2009) Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol 27: 91-97.
42. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
43. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.